Decentralized care pathway for cancer patients receiving oral treatment
Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Patients Receiving Oral Treatment for Cancer or Malignant Haemopathy (ACCELER PLATFORM)
This study is testing a new way for cancer patients on oral chemotherapy to receive care at home from a nurse instead of going to the hospital, to see if it makes them happier and helps them stick to their treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 33 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut Claudius Regaud Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT06797037 on ClinicalTrials.gov |
What this trial studies
This proof-of-concept study aims to assess the feasibility of a decentralized care pathway for patients with solid cancers or haematological malignancies who are receiving oral chemotherapy. The study will involve 33 patients and will replace traditional hospital visits with home visits by an advanced practice nurse to enhance patient care and convenience. The goal is to evaluate whether this approach can improve treatment adherence and patient satisfaction while maintaining safety and efficacy.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with solid cancers or haematological malignancies who are currently receiving oral retroceded therapy.
Not a fit: Patients who are pregnant, breastfeeding, or have conditions that hinder compliance with the study protocol may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a more convenient and patient-centered method of delivering oral chemotherapy.
How similar studies have performed: While this approach is innovative, similar decentralized care models have shown promise in improving patient outcomes in other settings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patient over 18. 2. A patient with solid cancer or haematological malignancy receiving oral retroceded therapy as part of standard management. 3. Patient with a performance index (ECOG): 0-2. 4. Patient contactable by telephone for follow-up by the Advanced Practice Nurse. 5. Patient willing to make two home visits within 6 months of inclusion. Exclusion Criteria: 1. Pregnant or breast-feeding patient. 2. Any psychological, family, geographical or social condition which, in the judgement of the oncologist, could potentially prevent the collection of informed consent or hinder compliance with the study protocol. 3. Patients deprived of their liberty by administrative or legal decision, or patients under guardianship.
Where this trial is running
Toulouse
- Institut Universitaire du Cancer de Toulouse - Oncopole — Toulouse, France (Recruiting)
Study contacts
- Study coordinator: Pierre BORIES
- Email: Bories.pierre@iuct-oncopole.fr
- Phone: 05 31 15 65 14
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.